Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
By Mariam SunnyEli Lilly NYSE:LLY on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk OMXCOP:NOVO_B with its Wegovy pill.Novo CEO Mike Doustdar said in August the company estimated…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.